YY1 binding within the human HSD3B2 gene intron 1 is required for maximal basal promoter activity: Identification of YY1 as the 3β1-A factor

Journal of Molecular Endocrinology

Volumn 33, Issue 1, 2004, Pages 99-119

  Foti, D M ^a   Reichardt, J K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ISOENZYME; NUCLEOTIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC CONSERVATION; HUMAN; HUMAN CELL; INTRON; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REPORTER GENE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

3-HYDROXYSTEROID DEHYDROGENASES; BASE SEQUENCE; DNA PRIMERS; DNA-BINDING PROTEINS; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; HUMANS; INTRONS; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; SP3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; YY1 TRANSCRIPTION FACTOR;

EID: 4444231362     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0330099     Document Type: Article

References (49)

1. Austen M, Lüscher B & Lüscher-Firzlaff JM 1997 Characterization of the transcriptional regulator YY1. Journal of Biological Chemistry 272 1709-1717.
2. Bartsch W, Klein H, Schiemann U, Bauer HW & Voigt KD 1990 Enzymes of androgen formation and degradation in the human prostate. Annals of the New York Academy of Sciences 595 53-66.
3. Becker KG, Jedlicka P, Templeton NS, Liotta L & Ozato K 1994 Characterization of hUCRBP (YY1, NF-E1, δ): a transcription factor that binds the regulatory regions of many viral and cellular genes. Gene 150 259-266.
4. Bosland MC 2000 The role of steroid hormones in prostate carcinogenesis. Journal of the National Cancer Institute. Monographs 2000 39-66.
5. Bovolenta C, Camorali L, Lorini LA, Vallanti G, Ghezzi S, Tambussi G, Lazzarin A & Poli G 1999 Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5Δ) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals. Journal of Immunology 163 6892-6897.
6. Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Carpten JD, Bleecker ER, Walsh PC, Trent JM et al. 2002 Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Research 62 1784-1789.
7. 4-isomerase type II gene expression: mechanisms of activation. In Proceedings of the 82nd Annual Meeting of Endocrine Society, Toronto, ON Canada 21-24 June 2000. P 1295
8. Dent CL & Latchman DS 1993 Transcription Factors: a Practical Approach, edn 2, p 11. Ed. DS Latchman. Oxford: IRL Press, Oxford University Press.
9. Eldar-Geva T, Hurwitz A, Vecsei P, Palti Z, Milwidsky A & Rosler A 1990 Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. New England Journal of Medicine 323 855-863.
10. Flanagan JR, Becker KG, Ennist DL, Gleason SL, Driggers PH, Levi BZ, Appella E & Ozato K 1992 Cloning of a negative transcription Factor that binds to the upstream conserved region of Moloney murine leukemia virus. Molecular and Cellular Biology 12 38-44.
11. 4-isomerase gene: activation by prolactin. Molecular Endocrinology 13 1084-1093.
12. 4-isomerase gene. Journal of Steroid Biochemistry and Molecular Biology 82 55-63.
13. Gann PH, Hennekens CH, Ma J, Longcope C & Stampfer MJ 1996 Prospective study of sex hormone levels and risk of prostate cancer. Journal of the National Cancer Institute 88 1118-1126.
14. Guerin S, Leclerc S, Verreault H, Labrie F & Luu-The V 1995 Overlapping cis-acting elements located in the first intron of the gene for type I 3β-hydroxysteroid dehydrogenase modulate its transcriptional activity. Molecular Endocrinology 9 1583-1597.
15. 4-isomerase in normal and tumoral target tissues. Journal of Steroid Biochemistry and Molecular Biology 76 213-225.
16. Kennett SB, Ulvadia AJ & Horowitz JM 1997 Sp3 encodes multiple proteins that differ in their capacity to stimulate or repress transcription. Nucleic Acids Research 25 3110-3117.
17. Kerr JM, Hiscock DRR, Grzesik W, Robey PG & Young MF 1997 The human bone sialoprotein gene contains an NF-E1/YY1 cis-acting sequence with putative regulatory activity. Calcified Tissue International 60 276-282.
18. Kim J & Shapiro DJ 1996 In simple synthetic promoters YY1-induced DNA bending is important in transcription activation and repression. Nucleic Acids Research 24 4341-4348.
19. Labrie F, Simard J, Luu-The V, Belanger A & Pelletier G 1992 Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. Journal of Steroid Biochemistry and Molecular Biology 43 805-826.
20. 4-isomerase gene and its expression in mammalian cells. Journal of Biological Chemistry 265 20469-20475.
21. 4-isomerase (3β-HSD) gene: adrenal and gonadal specificity. DNA and Cell Biology 10 701-711.
22. Lala DS, Rice DA & Parker KL 1992 Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Molecular Endocrinology 6 1249-1258.
23. 4-isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester. Journal of Biological Chemistry 272 7960-7967.
24. Leibovitz A, McCombs WM, Johnston D, McCoy CE & Stinson JC 1973 New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex. Journal of the National Cancer Institute 51 691-697.
25. Levine LS 2000 Congenital adrenal hyperplasia. Pediatrics in Review 21 159-170.
26. Luu-The V, Lachance Y, Labrie C, Leblanc G, Thomas JL, Strickler RC & Labrie F 1989 Full length cDNA structure and deduced amino acid sequence of human 3β-hydroxy-5-ene steroid dehydrogenase. Molecular Endocrinology 3 1310-1312.
27. Marker PC, Donjacour AA, Dahiya R & Cunha G 2003 Hormonal, cellular, and molecular control of prostatic development. Developmental Biology 253 165-174.
28. Marui S, Castro M, Latronico AC, Elias LL, Arnhold IJ, Moreira AC & Mendonca BB 2000 Mutations in the type II 3β -hydroxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clinical Endocrinology 52 67-75.
29. Mendonca BB, Russell AJ, Vasconcelos-Leite M, Arnhold IJP, Bloise W, Wajchenberg BL, Nicolau W, Sutcliffe RG & Wallace AM 1994 Mutation in 3β-hydroxysteroid dehydrogenase type II associated with pseudohermaphroditism in males and premature pubarche or cryptic expression in females. Journal of Molecular Endocrinology 12 119-122.
30. 4-isomerase close to D1S514 and the centromeric D1Z5 locus. Cytogenetics and Cell Genetics 69 59-62.
31. Morohashi K, Honda S, Inomata Y & Omura T 1992 A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. Journal of Biological Chemistry 267 17913-17919.
32. Morrison N, Nickerson DA, McBride MW, Mueller UV, Boyd E & Sutcliffe RG 1991 Regional chromosomal assignment of human 3-beta-hydroxy-5-ene steroid dehydrogenase to 1p13·1 by non-isotopic in situ hybridization. Human Genetics 87 223-235.
33. Natesan S & Gilman MZ 1993 DNA bending and orientation-dependent function of YY1 in the c-fos promoter. Genes and Development 7 2497-2509.
34. Nelson C, Hendy S, Reid K & Cavanagh J 2002 Acrylamide capture of DNA-bound complexes: electrophoretic purification of transcription factors. BioTechniques 32 808-815.
35. Pang S, Wang W, Rich B, David R, Chang YT, Carbunaru G, Myers SE, Howie AF, Smillie KJ & Mason JI 2002 A novel nonstop mutation in the stop codon and a novel missense mutation in the type II 3β-hydroxysteroid dehydrogenase (3β-HSD) gene causing, respectively, nonclassic and classic 3β-HSD deficiency congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 87 2556-2563.
36. Parvin JD, McCormick RJ, Sharp PA & Fisher DE 1995 Pre-bending of a promoter sequence enhances affinity for the TATA-binding factor. Nature 23 724-727.
37. Pizzorno MC 2001 Nuclear cathepsin B-like protease cleaves transcription factor YY1 in differentiated cells. Biochimica et Biophysica Acta 1536 31-42.
38. 4-isomerase in human adrenals and gonads. Molecular Endocrinology 5 1147-1157.
39. Ross RK & Schottenfeld D 1996 Prostate cancer. In Cancer Epidemiology and Prevention, edn 2, pp 1180-1206. Eds D Schottenfeld & J Fraumeni. Oxford: IRL Press, Oxford University Press.
40. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN & Henderson BE 1998 Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Research 58 4497-4504.
41. Safrany G & Perry RP 1993 Characterization of the mouse gene that encodes the δ/YY1/NF-E1/UCRBP transcription factor. PNAS 90 5559-5563.
42. Simard J, Rheaume E, Sanchez R, Laflamme N, de Launoit Y, Luu-The V, van Seters AP, Gordon RD, Bettendorf M & Heinrich U 1993 Molecular basis of congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency. Molecular Endocrinology 7 716-728.
43. 4-isomerase deficiency. Seminars in Reproductive Medicine 20 255-276.
44. Shi Y, Seto E, Chang LS & Shenk T 1991 Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 67 377-388.
45. Shi Y, Lee J-S & Galvin KM 1997 Everything you have ever wanted to know about Yin Yang 1. Biochimica et Biophysica Acta 1332 F49-F66.
46. Suske G 1999 The Sp-family of transcription factors. Gene 238 291-300.
47. Thomas MJ & Seto E 1999 Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 236 197-209.
48. Walowitz JL, Bradley ME, Chen S-J & Lee T-C 1998 Proteolytic regulation of the zinc finger transcription factor YY1, a repressor of muscle-restricted gene expression. Journal of Biological Chemistry 273 6656-6661.
49. White PC 2001 Congenital adrenal hyperplasias. Best Practice and Research. Clinical Endocrinology and Metabolism 15 17-41.